NEW YORK--(BUSINESS WIRE)--Kadmon Holdings, Inc. (NYSE:KDMN) (“Kadmon” or the “Company”) today provided a business update and reported financial and operational results for the three months ended March 31, 2017.
“We look forward to executing on our multiple clinical milestones in the second half of 2017, which include data readouts from our ongoing Phase 2 studies evaluating our ROCK2 inhibitor, KD025.”
“We have further streamlined our operations and reduced costs, allowing us to focus our resources towards rapidly advancing our clinical pipeline,” said Harlan W. Waksal, M.D., President and Chief Executive Officer at Kadmon. “We look forward to executing on our multiple clinical milestones in the second half of 2017, which include data readouts from our ongoing Phase 2 studies evaluating our ROCK2 inhibitor, KD025.”
Clinical and Research Update
KD025
The Company expects to report data from its three ongoing Phase 2 clinical trials as follows:
- Open-label, dose-finding clinical trial in chronic graft-versus-host disease – initial data expected Q3 2017
- Randomized, open-label clinical trial in idiopathic pulmonary fibrosis – initial data expected Q4 2017
- Randomized, placebo-controlled clinical trial in moderate to severe psoriasis – full data expected Q4 2017
Tesevatinib
- Dose-finding Phase 1 clinical trial in autosomal recessive polycystic kidney disease – expected to initiate Q2 2017
- Randomized, double-blind, placebo-controlled Phase 2 clinical trial in autosomal dominant polycystic kidney disease – expected to initiate Q3 2017
- Enrollment continues in the Company’s ongoing Phase 2 clinical trials in glioblastoma and in non-small cell lung cancer with brain or leptomeningeal metastases.
KD034
